Notice of Proposed Sale · 144
Organon & Co.
OGNNYSEEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ORGANON & CO.
- Issuer CIK
- 0001821825
- SEC file number
- 001-40235
- Phone
- (551) 430-6900
- Person for whose account securities are to be sold
- JULIANA P DRINANE
- Relationships to issuer
- Officer
- Street
- 30 Hudson Street, Floor 33
- City
- Jersey City
- State / country code
- NJ
- Postal code
- 07302
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 14,761 | 200,306.77 | 262,609,433 | 08/05/2026 | NYSE | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/07/2024 | Restricted Stock Vesting Under a Registered Plan | Issuer | 2,384 | N | 11/07/2024 | Not Applicable |
| Common | 12/13/2024 | Restricted Stock Vesting Under a Registered Plan | Issuer | 44 | N | 12/13/2024 | Not Applicable |
| Common | 03/14/2025 | Restricted Stock Vesting Under a Registered Plan | Issuer | 44 | N | 03/14/2025 | Not Applicable |
| Common | 03/29/2025 | Restricted Stock Vesting Under a Registered Plan | Issuer | 5,245 | N | 03/29/2025 | Not Applicable |
| Common | 03/31/2025 | Restricted Stock Vesting Under a Registered Plan | Issuer | 7,015 | N | 03/31/2025 | Not Applicable |
| Common | 06/13/2025 | Restricted Stock Vesting Under a Registered Plan | Issuer | 29 | N | 06/13/2025 | Not Applicable |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/05/2026
- Signed
- /s/ Juliana Papa Drinane
Company context
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.